000121055 001__ 121055
000121055 005__ 20240319081025.0
000121055 0247_ $$2doi$$a10.1016/j.autrev.2022.103167
000121055 0248_ $$2sideral$$a130383
000121055 037__ $$aART-2022-130383
000121055 041__ $$aeng
000121055 100__ $$aCarbonell, Cristina
000121055 245__ $$aStandardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)
000121055 260__ $$c2022
000121055 5060_ $$aAccess copy available to the general public$$fUnrestricted
000121055 5203_ $$aAim
Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non–SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with SSc using standardized incidence ratios (SIRs) and identified independent cancer risk factors in this population.
Material and methods
Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confidence intervals (CIs) relative to the general Spanish population were calculated.
Results
Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36–1.60; P < 0.001), and of lung (SIR 2.22, 95% CI 1.77–2.73; P < 0.001), breast (SIR 1.31, 95% CI 1.10–1.54; P = 0.003), and hematological (SIR 2.03, 95% CI 1.52–2.62; P < 0.001) cancers. Cancer was associated with older age at SSc onset (odds ratio [OR] 1.22, 95% CI 1.01–1.03; P < 0.001), the presence of primary biliary cholangitis (OR 2.35, 95% CI 1.18–4.68; P = 0.015) and forced vital capacity <70% (OR 1.8, 95% CI 1.24–2.70; P = 0.002). The presence of anticentromere antibodies lowered the risk of cancer (OR 0.66, 95% CI 0.45–0.97; P = 0.036).
Conclusions
Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk.
000121055 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000121055 590__ $$a13.6$$b2022
000121055 592__ $$a2.552$$b2022
000121055 591__ $$aIMMUNOLOGY$$b12 / 161 = 0.075$$c2022$$dQ1$$eT1
000121055 593__ $$aImmunology and Allergy$$c2022$$dQ1
000121055 593__ $$aImmunology$$c2022$$dQ1
000121055 594__ $$a23.3$$b2022
000121055 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000121055 700__ $$aMarcos, Miguel
000121055 700__ $$aGuillén-del-Castillo, Alfredo
000121055 700__ $$aRubio-Rivas, Manuel
000121055 700__ $$aArgibay, Ana
000121055 700__ $$aMarín-Ballvé, Adela
000121055 700__ $$aRodríguez-Pintó, Ignasi
000121055 700__ $$aBaldà-Masmiquel, Maria
000121055 700__ $$aCallejas-Moraga, Eduardo
000121055 700__ $$aColunga, Dolores
000121055 700__ $$0(orcid)0000-0002-9868-6498$$aSáez-Comet, Luis$$uUniversidad de Zaragoza
000121055 700__ $$aGonzález-Echávarri, Cristina
000121055 700__ $$aOrtego-Centeno, Norberto
000121055 700__ $$aMarí-Alfonso, Begoña
000121055 700__ $$aVargas-Hitos, José-Antonio
000121055 700__ $$aTodolí-Parra, José-Antonio
000121055 700__ $$aTrapiella, Luis
000121055 700__ $$aHerranz-Marín, María-Teresa
000121055 700__ $$aFreire, Mayka
000121055 700__ $$aCastro-Salomó, Antoni
000121055 700__ $$aPerales-Fraile, Isabel
000121055 700__ $$aMadroñero-Vuelta, Ana-Belén
000121055 700__ $$aSánchez-García, María-Esther
000121055 700__ $$aRuiz-Muñoz, Manuel
000121055 700__ $$aGonzález-García, Andrés
000121055 700__ $$aSánchez-Redondo, Jorge
000121055 700__ $$ade-la-Red-Bellvis, Gloria
000121055 700__ $$aFernández-Luque, Alejandra
000121055 700__ $$aMuela-Molinero, Alberto
000121055 700__ $$aLledó, Gema-María
000121055 700__ $$aTolosa-Vilella, Carles
000121055 700__ $$aFonollosa-Pla, Vicent
000121055 700__ $$aChamorro, Antonio-Javier
000121055 700__ $$aSimeón-Aznar, Carmen-Pilar
000121055 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000121055 773__ $$g21, 10 (2022), 103167 [10 pp.]$$pAutoimmun. Rev.$$tAUTOIMMUNITY REVIEWS$$x1568-9972
000121055 8564_ $$s647327$$uhttps://zaguan.unizar.es/record/121055/files/texto_completo.pdf$$yVersión publicada
000121055 8564_ $$s2443402$$uhttps://zaguan.unizar.es/record/121055/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000121055 909CO $$ooai:zaguan.unizar.es:121055$$particulos$$pdriver
000121055 951__ $$a2024-03-18-16:36:08
000121055 980__ $$aARTICLE